ISA104

Showing 1 posts of 1 posts found.

First patient dosed in phase 1 study for chronic hepatitis B treatment

August 31, 2023
Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B

ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …

Latest content